Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Viridian Therapeutics

Pharmaceutical intelligence for Viridian Therapeutics with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Assets
2

Recent signals(2)

RegulatoryJuly 3, 2026

FDA Approves BLA761530 (LUMVOA) from Viridian Therapeutics

The FDA has approved BLA761530, known as LUMVOA, submitted by Viridian Therapeutics.

ClinicalJune 26, 2026

Viridian Therapeutics initiates trial for VRDN-003 in Thyroid Eye Disease

Viridian Therapeutics is conducting a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of VRDN-003 in patients with Thyroid Eye Disease.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(1)

RegulatoryJuly 3, 2026

FDA Approves BLA761530 (LUMVOA) from Viridian Therapeutics

The FDA has approved BLA761530, known as LUMVOA, submitted by Viridian Therapeutics.

Clinical activity(1)

ClinicalJune 26, 2026

Viridian Therapeutics initiates trial for VRDN-003 in Thyroid Eye Disease

Viridian Therapeutics is conducting a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of VRDN-003 in patients with Thyroid Eye Disease.

Competitive activity

No signals indexed for this entity yet.

Assets

BLA761530 →
VRDN-003 →

Therapeutic areas

Monoclonal Antibody →
Oncology →
Ophthalmology →
Thyroid Eye Disease →

Indications

Thyroid Eye Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.